16,308 Shares in TransMedics Group, Inc. (NASDAQ:TMDX) Acquired by State of Alaska Department of Revenue

State of Alaska Department of Revenue bought a new stake in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 16,308 shares of the company's stock, valued at approximately $2,560,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. International Assets Investment Management LLC acquired a new position in shares of TransMedics Group in the second quarter valued at approximately $47,000. USA Financial Formulas purchased a new position in shares of TransMedics Group during the 3rd quarter worth $55,000. J.Safra Asset Management Corp boosted its holdings in shares of TransMedics Group by 649.2% during the second quarter. J.Safra Asset Management Corp now owns 442 shares of the company's stock worth $67,000 after purchasing an additional 383 shares during the last quarter. Signaturefd LLC grew its position in shares of TransMedics Group by 26.6% in the second quarter. Signaturefd LLC now owns 443 shares of the company's stock valued at $67,000 after purchasing an additional 93 shares during the period. Finally, Fidelis Capital Partners LLC acquired a new position in TransMedics Group in the first quarter valued at $35,000. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at TransMedics Group

In other TransMedics Group news, insider Anil P. Ranganath sold 4,289 shares of TransMedics Group stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $152.20, for a total transaction of $652,785.80. Following the sale, the insider now directly owns 8,893 shares in the company, valued at $1,353,514.60. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, insider Nicholas Corcoran sold 10,000 shares of the stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $176.02, for a total transaction of $1,760,200.00. Following the transaction, the insider now owns 21,105 shares of the company's stock, valued at approximately $3,714,902.10. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Anil P. Ranganath sold 4,289 shares of the business's stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $152.20, for a total value of $652,785.80. Following the completion of the sale, the insider now directly owns 8,893 shares of the company's stock, valued at approximately $1,353,514.60. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 61,247 shares of company stock valued at $9,518,181 in the last ninety days. Insiders own 7.00% of the company's stock.

TransMedics Group Stock Up 0.5 %

Shares of NASDAQ:TMDX traded up $0.43 during mid-day trading on Friday, hitting $82.40. 1,817,565 shares of the company traded hands, compared to its average volume of 942,177. The firm's 50 day simple moving average is $142.38 and its 200 day simple moving average is $139.36. The firm has a market cap of $2.77 billion, a P/E ratio of 88.98 and a beta of 1.99. The company has a debt-to-equity ratio of 2.42, a quick ratio of 8.48 and a current ratio of 8.20. TransMedics Group, Inc. has a 52-week low of $38.13 and a 52-week high of $177.37.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last posted its earnings results on Monday, October 28th. The company reported $0.12 EPS for the quarter, missing analysts' consensus estimates of $0.29 by ($0.17). The firm had revenue of $108.76 million for the quarter, compared to analyst estimates of $115.00 million. TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The company's revenue for the quarter was up 63.7% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.12) earnings per share. On average, equities analysts anticipate that TransMedics Group, Inc. will post 1.11 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have issued reports on TMDX. JPMorgan Chase & Co. decreased their price target on TransMedics Group from $173.00 to $116.00 and set an "overweight" rating on the stock in a research note on Tuesday. Needham & Company LLC lowered their target price on shares of TransMedics Group from $208.00 to $109.00 and set a "buy" rating for the company in a report on Tuesday. Piper Sandler reaffirmed an "overweight" rating and set a $180.00 price target on shares of TransMedics Group in a research note on Tuesday. Baird R W raised shares of TransMedics Group to a "strong-buy" rating in a research note on Tuesday, September 24th. Finally, Canaccord Genuity Group cut their target price on TransMedics Group from $169.00 to $109.00 and set a "buy" rating on the stock in a research report on Tuesday. One research analyst has rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Buy" and a consensus price target of $144.80.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.